Intergroup Randomized Phase II Four Arm Study in Patients > 60 With Previously Untreated Mantle Cell Lymphoma Of Therapy With: Arm A = Rituximab + Bendamustine Followed by Rituximab Consolidation (RB -> R); Arm B = Rituximab + Bendamustine + Bortezomib Followed by Rituximab Consolidatoin (RBV -> R), Arm C = Rituximab + Bendamustine Followed by Lenalidomide + Riuximab Consolidation (RB -> LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed By Lenalidomide + Rituximab Consolidation (RBV -> LR)
ID Number 58-0056-01411Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is two fold and has two steps of study treatment:
1: In step 1, to find out what effects, good and bad, the addition of bortezomib to rituximab plus bendamustine has on you and your lymphoma compared to rituximab plus bendamustine alone.
2: In step 2, to find out what effects, good and bad, continuing study treatment after step 1 with lenalidomide plus rituximab has on you and your lymphoma compared to continuing study treatment with rituximab alone.
Recruiting Patients: Yes